Risperdal Lawsuits Now Being Filed by Bernstein Liebhard LLP on Behalf of Men and Boys Who Allegedly Suffered Gynecomastia Due to the Antipsychotic Medication

April 2, 2014

The Firm continues to investigate Risperdal lawsuits that allege the atypical antipsychotic drug caused male breast development, or gynecomastia.

New York, New York (PRWEB) April 02, 2014

The nationwide law firm of Bernstein Liebhard LLP is actively filing Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) on behalf of individuals who allegedly suffered gynecomastia, or male breast growth, due to their use of the atypical antipsychotic. On March 26, 2014, the Firm filed a claim on behalf of a man who allegedly developed gynecomastia due to his use of Risperdal, as well as a related drug called Invega, for nearly 15 years. The complaint was filed in Pennsylvania’s Philadelphia Court of Common Pleas, where dozens of other Risperdal lawsuits involving male breast development have been consolidated in a mass tort proceeding. (Case No.140304081)

“This complaint joins scores of other Risperdal lawsuits filed in Pennsylvania that make similar allegations about the medication’s link to gynecomastia. Our Firm expects that the litigation surrounding Risperdal and male breast development will continue to grow in the coming months,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.

Risperdal Lawsuits

According to court documents, Risperdal is an atypical antipsychotic drug marketed by Johnson & Johnson’s Janssen Pharmaceuticals unit that is used to treat adult and adolescent schizophrenia, as well as bipolar disorder in adults and children ages 10-to-17. Risperdal is also approved to treat irritability in children (5-to-16 years of age) with autistic disorder. Invega, which is also marketed by Janssen, contains an active metabolite of risperidone, the active ingredient in Risperdal.

Court records indicate that some 350 Risperdal lawsuits are now pending in the mass tort litigation underway in the Philadelphia Court of Common Pleas, including dozens that allege the drug can cause gynecomastia in men and boys. Plaintiffs also allege that Johnson & Johnson and Janssen marketed Risperdal for off-label uses, including the treatment of children long before pediatric indications were approved in 2006. (Risperdal Litigation, case number 100300296)

In November, Johnson & Johnson and Janssen agreed to pay $2.2 billion to resolve a lawsuit filed by the U.S. Department of Justice that accused the companies of improperly marketing several medications, including Risperdal and Invega. According to the government, the settlement ranked among the largest ever involving healthcare fraud. Among other things, the Department of Justice claimed that the companies had engaged in off-label marketing of Risperdal, and downplayed its association with serious side effects, including male breast development. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Men and boys who allegedly developed gynecomastia due to their use of Risperdal or Invega may be entitled to compensation for their injury-related damages. Learn more about filing a Risperdal lawsuit at Bernstein Liebhard LLP’s website. Free case reviews may also be obtained by calling the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016


ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com



For the original version on PRWeb visit: http://www.prweb.com/releases/risperdal-lawsuit/risperdal-gynecomastia/prweb11730113.htm

Source: prweb

comments powered by Disqus